How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

136 results for

Beau Lines

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Screening and Management of Late and Long-term Consequences of Myeloma and its Treatment

University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK Summary A growing population of long-term survivors of myeloma is now accumulating the ‘late effects’ not only of myeloma itself, but also of several lines of treatment given throughout the course of the disease. It is thus important to recognise the cumulative burden of the disease and treatment-related toxicity in both the stable and active phases of myeloma, some of which is unlikely to be detected by routine monitor- ing. We (...) ’ (http://www.cancer.gov/d ictionary). With the improved outcomes for a range of cancers, increasing attention is merited for late disease and treatment effects and their impact on patient experience (Denlinger et al, 2014). Late effects are increasingly relevant to myeloma patients, given that they can often live for over a decade post-diagnosis, have repeated lines of complex therapies and have long-term disease control in the absence of cure. Late effects in myeloma Life expectancy for myeloma

2017 British Committee for Standards in Haematology

22. Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities

, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished

2017 World Health Organisation Guidelines

23. No Clinical Difference in the Osseointegration of Zirconia Dental Implants Compared to Titanium Dental Implants at 1 Year

to traditional titanium implants? Clinical Bottom Line Based on 1-year survival rates, zirconia implants have the potential to be an alternative to titanium implants; however, further studies are needed to establish how their long-term survival rates compare to titanium, as well as to establish the risk for technical/hardware and biological complications. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1 (...) mcneillb@livemail.uthscsa.edu Author Beau McNeill Co-author(s) Co-author(s) e-mail Faculty mentor/Co-author Jeffrey L. Hicks, BS, DDS Faculty mentor/Co-author e-mail HicksJ@uthscsa.edu Basic Science Rationale (Mechanisms that may account for and/or explain the clinical question, i.e. is the answer to the clinical question consistent with basic biological, physical and/or behavioral science principles, laws and research?) None available Comments and Evidence-Based Updates on the CAT (FOR PRACTICING

2017 UTHSCSA Dental School CAT Library

24. Midostaurin for the indication of Acute Myeloid Leukaemia

therapy. De- pending on line of the induction and consolidation therapy (i.e., first induction, sec- ond induction etc.), variations might occur and mitoxantrone might be added during the second induction or third consolidation. MeSH terms: midostaurin (MeSH Unique ID: C059539) Comparison ? standard induction and consolidation chemotherapy (see above). Eligible patients might receive SCT. ? induction and consolidation chemotherapy, except daunorubicin 90 mg/m 2 /day (instead of 60 mg/m 2 /day) is used

2017 EUnetHTA

25. Acute lymphoblastic leukemia

positive ALL: 4.1.1. No TKI has been clearly shown to be superior upfront. As most studies have assessed high does imatinib (600 – 800mg) we recommend that it be used first line 4.1.1.1. Patients with intolerance to, or not achieving an adequate response to, imatinib should be switched to a second generation TKI such as dasatinib 4.1.1.2. Ponatinib should be used in patients with a T315I mutation 4.1.1.3. For patients with CNS diseae at diagnosis dasatinib should be used upfront. 4.1.2. Ph/BCR-ABL

2016 CPG Infobase

26. Epilepsy in Pregnancy

be an opportunity to screen for structural abnormalities. The fetal anomaly scan at 18 +0 –20 +6 weeks of gestation can identify major cardiac defects in addition to neural tube defects. All WWE should be offered a detailed ultrasound in line with the National Health Service Fetal Anomaly Screening Programme standards. How should women taking AEDs be monitored to avoid worsening of seizures? For WWE taking AEDs, is dose escalation better than expectant management? Based on current evidence, routine monitoring (...) should be offered a detailed ultrasound in line with the National Health Service Fetal Anomaly Screening Programme standards. Biochemical screening with maternal serum alphafetoprotein when combined with ultrasonography increases the detection rate for neural tube defects to 94–100%, 56 thereby offering the opportunity to detect these abnormalities in early gestation for WWE. No studies have assessed the role of routine fetal echocardiography in detecting congenital heart disease in babies of WWE

2016 Royal College of Obstetricians and Gynaecologists

28. Childhood Cancer Genomics (PDQ®): Health Professional Version

, a gene involved in purine biosynthesis.[ ] Mutations were observed in 13.0% of a Chinese cohort and 2.7% of a German cohort, and were observed in patients with on-treatment relapses. The PRSP1 mutations observed in relapsed cases induce resistance to thiopurines in leukemia cell lines. CREBBP mutations are also enriched at relapse and appear to be associated with increased resistance to glucocorticoids.[ , ] With increased understanding of the genomics of relapse, it may be possible to tailor upfront

2018 PDQ - NCI's Comprehensive Cancer Database

29. Initial Diagnostic Workup of Acute Leukemia

have been described and included in the most recent revision of the WHO Classi?cation of Tumours of Haematopoietic and Lymphoid Tissues 8 ; the most well-known of which include AML with germline CEBPA mutation, 46,47 myeloid or lymphoid neoplasms with germline RUNX1 mutation, 48,51 myeloid or lymphoid neoplasms with germ- line ANKRD26 mutation, 52,53 and myeloid neoplasms with GATA2 mutation, 54,58 among others. In addition, AL arising in patients with a background of inherited bone marrow (BM

2016 College of American Pathologists

30. Management of AML in Pregnancy

treatment. According to the UK Teratology Information Service (UKTIS), the first choice antiemetic drugs are the antihistamines, cyclizine and promethazine (UKTIS ). Prochlorperazine and metoclopromide are considered second line agents because they may be associated with maternal dystonic reactions (UKTIS ). Ondansetron can be used in cases where first and second line antiemetic therapies have been unsuccessful (Einarson et al , ). Antibiotics Patients usually suffer severe neutropenia either (...) , M.J. , Porwit, A. , Harris, N.L. , Le Beau, M.M. , Hellström‐Lindberg, E. , Tefferi, A. & Bloomfield, C.D. ( 2009 ) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukaemia: rationale and important changes . Blood , 114 , 937 – 951 . Wagner, V.M. , Hill, J.S. , Weaver, D. & Baehner, R.L. ( 1980 ) Congenital abnormalities in baby born to cytarabine treated mother . Lancet , 316 , 98 – 99 . Weisz, B. , Meirow, D. , Schiff, E. & Lishner, M

2015 British Committee for Standards in Haematology

31. Laboratory diagnosis of non-immune hereditary red cell membrane disorders

are composed of linear repeats (i.e. homologous triple helical segments). Each repeat is about 106 amino acids in length and is organized into a triple helix. The arrangement is that helix 2 and 3 in one repeat lock into helix 1 of the next repeat. The self‐association site (circle with dotted line) comprises the N‐terminus of α chain (mainly the αI domain, M r 80 kDa) and the C‐terminus of the β chain. Mutations in Spα LELY allele affect repeats α18 and α21. Mutations in the α‐spectrin and β‐spectrin

2015 British Committee for Standards in Haematology

32. Pediatric nail consultation in an academic center in Belgium: a 10-year retrospective study. (Abstract)

Fabiola Children's University Hospital. The data was synthesized from information obtained through medical records as well as from photographs taken during consultation. Follow-up was completed by phone interview.Three hundred and one patients were included. The majority of nail abnormalities involved the toenails (57.6%). The most common clinical signs were, in descending order, Beau's lines, pachyonychia, subungual hyperkeratosis and onycholysis. The most frequent diagnoses were fever-related Beau's (...) lines or onychomadesis (9.7%), trachyonychia (8.4%), longitudinal melanonychia (8.1%) and congenital malalignment of the great toenail (8.1%). The main diagnoses by age group were: congenital hypertrophy of the lateral nail folds (21.4%) [0 to 2 years old]; fever-related Beau's lines or onychomadesis (21%) [2 to 6 years old]; trachyonychia (22%) [6 to 12 years old]; juvenile ingrown nail (21.4%) [12 to 18 years old]. Management included clinical observation for 119 patients and specific advices

2019 Journal of the European Academy of Dermatology and Venereology

33. Cardiac Pacing and Cardiac Resynchronization Therapy

professionals involved with the medical care of patients with this path- ology. Selected experts in the ?eld undertook a comprehensive review ofthepublishedevidencefordiagnosis,managementand/orprevention of a given condition, according to ESC Committee for Practice Guide- lines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk–bene?t ratio. Estimates of expected health outcomes for larger populations were included, where data exist

2013 European Society of Cardiology

34. Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®): Health Professional Version

diagnosis of MDS when morphological characteristics are not observed. f The diagnostic criteria for childhood MDS (refractory cytopenia of childhood [RCC]-provisional entry) include: 1) persistent cytopenia of 1–3 cell lines with <5% bone marrow blasts, <2% peripheral blood blasts, and no ringed sideroblasts and 2) dysplastic changes in 1–3 lineages should be present. Table 4. Definitions for Minimal Diagnostic Criteria for Childhood Myelodysplastic Syndrome (MDS) (Provisional Entity: Refractory

2017 PDQ - NCI's Comprehensive Cancer Database

35. Acute and Chronic Heart Failure

12.3 Invasive monitoring . . . . . . . . . . . . . . . . . . . . . . . .1831 12.3.1 Intra-arterial line . . . . . . . . . . . . . . . . . . . . . . .1831 12.3.2 Pulmonary artery catheterization . . . . . . . . . . . .1831 12.4 Monitoring after stabilization . . . . . . . . . . . . . . . . . .1831 12.5 Other in-patient assessments . . . . . . . . . . . . . . . . .1831 12.6 Readiness for discharge . . . . . . . . . . . . . . . . . . . . .1831 12.7 Special patient populations (...) of the indication for mineralocorticoid (aldosterone) receptor antagonists (MRAs); (ii) a new indication for the sinus node inhibitor ivabradine; (iii) an expanded indication for cardiac resynchronization therapy (CRT); (iv) new information on the role of coronary revascularization in HF; (v) recognition of the growing use of ventricular assist devices; and (vi) the emergence of transcatheter valve interventions. There are also changes to the structure and format of the guide- lines. Therapeutic recommendations

2012 European Society of Cardiology

36. Suicide Prevention Interventions and Referral/Follow-up Services

report when possible; however, when describing results from primary studies, we use terminology as reported in the original articles in order to describe outcomes consistent with the primary studies. 9 Suicide Prevention Interventions and Referral/Follow-up Services: A Systematic Review Evidence-based Synthesis Program Figure 1. Suicide Prevention Analytical Model Population-level interventions Help seeking resources (e.g., crisis • lines) Public education (e.g., PSAs on • suicide awareness

2012 Veterans Affairs Evidence-based Synthesis Program Reports

37. Involvement of Nail Apparatus in Pemphigus Vulgaris in Ethnic Poles Is Infrequent Full Text available with Trip Pro

apparatus changes included, by order of frequency, paronychia, nail discoloration, onychorrhexis, Beau lines, periungual hemorrhages, onychomadesis, cross-ridging, onycholysis, and trachyonychia. The average time between the onset, as recalled by patients, and the diagnosis of pemphigus vulgaris with direct immunofluorescence was not statistically different in PV patients with and without nail apparatus lesions. In this article the molecular and immunological rationale for of periungual involvement

2018 Frontiers in medicine

38. ASPEN Clinical Guidelines: Support of Pediatric Patients with Intestinal Failure at Risk of Parenteral Nutrition - Associated Liver Disease

. After the author response to the initial reviews, the guideline was reviewed and approved by the A.S.P.E.N. Board of Directors and their legal consultant. Results Four questions were developed to be addressed by this guide- line. The questions and recommendations are summarized in Table 1. For the current Clinical Guideline, the following terms were used to search PubMed and CINAHL until May 2013: intestinal failure, short bowel syndrome, clinical outcomes, lipid, bloodstream infection, team (...) et al, 2012 54 Retrospective case series HPN patients, N = 4 Report case series of catheter complications after use of 70% ethanol lock 3 times weekly Thrombosis in line when ethanol withdrawn at 413 days (n = 1), at 168 days (n = 1), at 9 days (n = 1), and CVC occlusion at 3 days (n = 1). The occlusion cleared after stopping ethanol lock. Wales et al, 2011 55 Retrospective case series HPN patients with at least 1 previous CLABSI. N = 10 Median age 44 months (range, 31–129 months) Body weight: 5

2014 American Society for Parenteral and Enteral Nutrition

39. Liver Transplantation, evaluation of the pediatric patient

symptoms, including those associated with PALF, and preclude the need for LT. LT is an accepta- ble therapeutic option for patients with FAOD who present with fulminant liver failure, but fail medical and dietary intervention. 308 Recommendations: 68. Management of FAOD with diet and intrave- nous glucose should be the ?rst line of therapy. (2-B) 69. Patients with FAOD should be considered for LT evaluation if they experience recurrent episodes of PALF or have failed medical therapy. (2-B) HEPATOLOGY

2014 American Association for the Study of Liver Diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>